What Do Tesla Delivery Numbers Mean for Tesla Stock?
Tesla (NASDAQ:TSLA) released Q1 delivery numbers, showing a substantial slowdown…
Sell
13
PETS Quote, Financials, Valuation and Earnings
Last price:
$3.05
Seasonality move
:
14.3%
Day range:
$3.00 - $3.17
52-week range:
$2.90 - $6.85
Dividend yield:
0%
P/E ratio:
304.00x
P/S ratio:
0.26x
P/B ratio:
0.65x
Volume:
282.5K
Avg. volume:
218.3K
1-year change:
-26.57%
Market cap:
$62.8M
Revenue:
$281.1M
EPS (TTM):
$0.01
Analysts' Opinion
-
Consensus RatingPetMed Express has received a consensus rating of Leans Bearish. The company's average rating is a Leans Bearish based on 0 Buy ratings, 1 Hold rating, and 1 Sell rating.
-
Price Target UpsideAccording to analysts' consensus price target of $3.75, PetMed Express has an estimated upside of 23.36% from its current price of $3.04.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.50 representing 100% downside risk from its current price of $3.04.
Fair Value
-
According to the consensus of 2 analysts, PetMed Express has 23.36% upside to fair value with a price target of $3.75 per share.
PETS vs. S&P 500
-
Over the past 5 trading days, PetMed Express has underperformed the S&P 500 by -18.06% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
PetMed Express does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
PetMed Express revenues have been falling on a year-over-year basis for 3 quarters in a row. In the most recent quarter PetMed Express reported revenues of $53M.
Earnings Growth
-
PetMed Express has grown year-over-year earnings for 1 quarter straight. In the most recent quarter PetMed Express reported earnings per share of -$0.03.
Enterprise value:
12.7M
EV / Invested capital:
--
Price / LTM sales:
0.26x
EV / EBIT:
19.40x
EV / Revenue:
0.05x
PEG ratio (5yr expected):
--
EV / Free cash flow:
14.86x
Price / Operating cash flow:
73.74x
Enterprise value / EBITDA:
1.69x
Gross Profit (TTM):
$68.4M
Return On Assets:
0.23%
Net Income Margin (TTM):
0.15%
Return On Equity:
0.37%
Return On Invested Capital:
0.37%
Operating Margin:
-0.85%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $259.2M | $277M | $247M | $65.3M | $53M | |
| Gross Profit | $71.7M | $77.9M | $68.4M | $17.9M | $14.9M | |
| Operating Income | $11.1M | -$4.5M | $655K | -$3.1M | -$450K | |
| EBITDA | $14.4M | $1.6M | $7.5M | -$1.3M | $1.1M | |
| Diluted EPS | $0.55 | -$0.38 | $0.01 | -$0.10 | -$0.03 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $141M | $142.9M | $134M | $95.5M | $68.4M | |
| Total Assets | $167.4M | $168.4M | $165.1M | $173.4M | $144.8M | |
| Current Liabilities | $26.9M | $26.3M | $31.1M | $72.4M | $48M | |
| Total Liabilities | $28.2M | $27.5M | $31.5M | $73.3M | $48.6M | |
| Total Equity | $139.1M | $140.9M | $133.6M | $100.1M | $96.2M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $26.8M | $6.9M | $4.8M | -$2.6M | -$1.2M | |
| Cash From Investing | -$8.8M | -$41.4M | -$4M | -$1.4M | -$777K | |
| Cash From Financing | -$24.5M | -$18.6M | -$194K | -$15K | -$1K | |
| Free Cash Flow | $23M | $1.7M | $855K | -$3.7M | -$1.9M | |
PETS
Sector
Market Cap
$62.8M
$399.8M
Price % of 52-Week High
44.38%
63.45%
Dividend Yield
0%
0%
Shareholder Yield
--
3.76%
1-Year Price Total Return
-26.57%
-21.82%
Beta (5-Year)
0.990
0.832
Dividend yield:
0%
Annualized payout:
$0.60
Payout ratio:
54.34%
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$3.37
200-day SMA
Sell
Level
$4.21
Bollinger Bands (100)
Sell
Level
4 - 5.3
Chaikin Money Flow
Sell
Level
-6.9M
20-day SMA
Sell
Level
$3.82
Relative Strength Index (RSI14)
Sell
Level
26.33
ADX Line
Sell
Level
34.68
Williams %R
Buy
Level
-94.6565
50-day SMA
Sell
Level
$4.24
MACD (12, 26)
Sell
Level
-0.31
25-day Aroon Oscillator
Sell
Level
-32
On Balance Volume
Sell
Level
-21.9M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (3.0683)
Buy
CA Score
(Annual)
Level (0.4891)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (4)
Buy
Ohlson Score
Level (0.056)
Buy
Piotroski F Score
(Annual)
Level (5)
Buy
Quality Ratio Score
Level (6)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
PetMed Express Inc along with its subsidiaries is a nationwide pet pharmacy. The company markets prescription and non-prescription pet medications, health products, and supplies for dogs and cats, direct to the consumer. The company generates its revenue by selling pet medications and pet supplies mainly to retail consumers.
Stock Forecast FAQ
In the current month, PETS has received 0 Buy ratings 1 Hold ratings, and 1 Sell ratings. The PETS average analyst price target in the past 3 months is $3.75.
-
Where Will PetMed Express Stock Be In 1 Year?
According to analysts, the consensus estimate is that PetMed Express share price will rise to $3.75 per share over the next 12 months.
-
What Do Analysts Say About PetMed Express?
Analysts are divided on their view about PetMed Express share price and where it will be in the next 12 months. The majority of analysts rate the stock a Sell. However, a smaller subset of analysts suggest that PetMed Express is a Buy and believe this share price will drop from its current level to $4.00.
-
What Is PetMed Express's Price Target?
The price target for PetMed Express over the next 1-year time period is forecast to be $3.75 according to 2 Wall Street analysts, 0 of them rate the stock a Buy, 1 rates the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is PETS A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for PetMed Express is a Leans Bearish. 1 of 2 analysts rates the stock a Leans Bearish at this time.
-
How Can I Buy Shares Of PETS?
You can purchase shares of PetMed Express via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase PetMed Express shares.
-
What Is The PetMed Express Share Price Today?
PetMed Express was last trading at $3.05 per share. This represents the most recent stock quote for PetMed Express. Yesterday, PetMed Express closed at $3.04 per share.
-
How To Buy PetMed Express Stock Online?
In order to purchase PetMed Express stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Chewy a Growth Stock to Buy?
It might be a surprise to learn that during the…
Is Realty Income the Best Dividend Stock to Buy Long-Term?
Realty Income (NYSE:O) is a longstanding real estate investment trust…
Stock Ideas
Sell
45
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 33x
Buy
53
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Sell
50
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 38x
Alerts
Buy
52
RGC alert for Apr 12
Regencell Bioscience Holdings [RGC] is up 29.14% over the past day.
Buy
52
SLP alert for Apr 12
Simulations Plus [SLP] is up 26.73% over the past day.
Buy
89
GDXU alert for Apr 12
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is up 15.9% over the past day.
